Beijing sunho Pharmaceutical Co., Ltd. always adheres to the corporate culture concept of “Surpassing self and creating development”.Since the company was founded in 2000, it has been relying on its strong R&D advantages, and it has developed into a leading pharmaceutical company driven by  production, and pharmaceutical R&D. Sales.The company was successfully listed on the 3rd board of Zhongguancun of the Shenzhen Stock Exchange in August 2007 with a stock code of 430017. The total assets are about 1 billion yuan and the total number of employees is more than 700. Since its foundation , the company has been focusing on the research and development of drugs, with scientific and technological innovation as the leading factor and making unremitting efforts to realize the vision of becoming an outstanding international advanced generic drug service provider.

Sunho Pharmaceutical currently has production bases in Beijing and Guangdong, and holds Changchun Tiancheng  Pharmaceutical Co., Ltd. In 2017, Sunho Pharmaceutical cooperated with the Chinese Academy of Sciences to establish the Beijing Center for Drug Innovation Research Institute of the Chinese Academy of Sciences. In 2018, the South China Center for Drug Innovation Research Institute of the Chinese Academy of Sciences will also be established to provide CMC, CRO, and CMO covering the full value chain of drug innovation and R&D. service. The second production base in Beijing is currently under construction, with an investment of about 700 million yuan. The production line for pharmaceutical preparations will be integrated with the innovation of new drugs. The production line will meet the standards of the EMA  and the FDA. The products will be exported to Europe, America and other places.

Sunho Pharmaceutical has been rated as a high-tech enterprise and a key high-tech enterprise of the National Torch Plan for several consecutive years. It has won more than 10 honorary titles such as the National Technology Innovation Guidance Project, and has more than 20 projects that have been awarded the National Technology Innovation Fund and other national-,Provincial as well as municipal level funding.

Sunho Pharmaceutical currently has 9 production lines that meet the GMP requirements. The freeze-dried and small-volume liquid injection workshop of Phase I of Guangdong Xinghong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the subsidiary, was the first batch of GMP certified in 2010, and was also the first domestic production workshop adopting international advanced liquid nitrogen freeze-drying technology. In the second phase, a small-volume injection line, freeze-dried powder injection line and oral solid preparation line meeting the US FDA and EU EMA standards are under construction, covering the production of oncology drugs and sustained release formulations.

Sunho Pharmaceuticals is committed to strengthening industrialization through the gradual application of profound technology accumulation to product production. By improving the marketing structure and expanding  the sales channels, more varieties will be more rapidly promoted to the market and developed into large-scale pharmaceutical companies that are driven by R&D to drive production and produce back-fed R&D.